HUBERT, Mathieu; GUIVEL-BENHASSINE, Florence; BRUEL, Timothée; PORROT, Françoise; PLANAS, Delphine; VANHOMWEGEN, Jessica; WIEDEMANN, Aurélie; BURREL, Sonia; MAROT, Stéphane; PALICH, Romain; MONSEL, Gentiane; DIOMBERA, Harouna; GALLIEN, Sébastien; LOPEZ-ZARAGOZA, Jose Luis; VINDRIOS, William; TAIEB, Fabien; FERNANDES-PELLERIN, Sandrine; DELHAYE, Maurine; LAUDE, Hélène; AROWAS, Laurence; UNGEHEUER, Marie-Noelle; HOCQUELOUX, Laurent; POURCHER, Valérie; PRAZUCK, Thierry; MARCELIN, Anne-Geneviève; LELIÈVRE, Jean-Daniel; BATÉJAT, Christophe; LÉVY, Yves; MANUGUERRA, Jean-Claude; SCHWARTZ, Olivier

doi:10.1016/j.chom.2023.05.001

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

HUBERT, Mathieu
Virus et Immunité - Virus and immunity [CNRS-UMR3569]

GUIVEL-BENHASSINE, Florence
Virus et Immunité - Virus and immunity [CNRS-UMR3569]

BRUEL, Timothée
Virus et Immunité - Virus and immunity [CNRS-UMR3569]
Vaccine Research Institute [Créteil, France] [VRI]

HUBERT, Mathieu
Virus et Immunité - Virus and immunity [CNRS-UMR3569]

GUIVEL-BENHASSINE, Florence
Virus et Immunité - Virus and immunity [CNRS-UMR3569]

BRUEL, Timothée
Virus et Immunité - Virus and immunity [CNRS-UMR3569]
Vaccine Research Institute [Créteil, France] [VRI]

PORROT, Françoise
Virus et Immunité - Virus and immunity [CNRS-UMR3569]

PLANAS, Delphine
Virus et Immunité - Virus and immunity [CNRS-UMR3569]
Vaccine Research Institute [Créteil, France] [VRI]

VANHOMWEGEN, Jessica
Environnement et Risques infectieux - Environment and Infectious Risks [ERI]

WIEDEMANN, Aurélie
Vaccine Research Institute [Créteil, France] [VRI]
Institut Mondor de Recherche Biomédicale [IMRB]

BURREL, Sonia
Microbiologie Fondamentale et Pathogénicité [MFP]

MAROT, Stéphane
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
CHU Charles Foix [AP-HP]

PALICH, Romain
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
CHU Charles Foix [AP-HP]

MONSEL, Gentiane
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
CHU Charles Foix [AP-HP]

DIOMBERA, Harouna
Vaccine Research Institute [Créteil, France] [VRI]
Institut Mondor de Recherche Biomédicale [IMRB]

GALLIEN, Sébastien
Groupe Henri Mondor-Albert Chenevier

LOPEZ-ZARAGOZA, Jose Luis
Groupe Henri Mondor-Albert Chenevier

VINDRIOS, William
Groupe Henri Mondor-Albert Chenevier

TAIEB, Fabien
Centre Médical de l'Institut Pasteur [CMIP]

FERNANDES-PELLERIN, Sandrine
Plate-forme d’Investigation Clinique / Clinical Investigation Platform [ICAReB-Clin]

DELHAYE, Maurine
Plate-forme d’Investigation Clinique / Clinical Investigation Platform [ICAReB-Clin]

LAUDE, Hélène
Plate-forme d’Investigation Clinique / Clinical Investigation Platform [ICAReB-Clin]

AROWAS, Laurence
Plate-forme d’Investigation Clinique / Clinical Investigation Platform [ICAReB-Clin]

UNGEHEUER, Marie-Noelle
Plate-forme d’Investigation Clinique / Clinical Investigation Platform [ICAReB-Clin]

HOCQUELOUX, Laurent
Centre Hospitalier Régional d'Orléans [CHRO]

POURCHER, Valérie
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
CHU Charles Foix [AP-HP]

PRAZUCK, Thierry
Centre Hospitalier Régional d'Orléans [CHRO]

MARCELIN, Anne-Geneviève
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
CHU Charles Foix [AP-HP]

LELIÈVRE, Jean-Daniel
Vaccine Research Institute [Créteil, France] [VRI]
Institut Mondor de Recherche Biomédicale [IMRB]
Groupe Henri Mondor-Albert Chenevier

BATÉJAT, Christophe
Environnement et Risques infectieux - Environment and Infectious Risks [ERI]

LÉVY, Yves
Vaccine Research Institute [Créteil, France] [VRI]
Institut Mondor de Recherche Biomédicale [IMRB]
Groupe Henri Mondor-Albert Chenevier

MANUGUERRA, Jean-Claude
Environnement et Risques infectieux - Environment and Infectious Risks [ERI]

SCHWARTZ, Olivier
Virus et Immunité - Virus and immunity [CNRS-UMR3569]
Vaccine Research Institute [Créteil, France] [VRI]

< Réduire

Langue

Article de revue

Ce document a été publié dans

Cell Host & Microbe. 2023-06-14, vol. 31, n° 6, p. 937-948.e4

Résumé en anglais

Mpox virus (MPXV) caused a multi-country outbreak in non-endemic areas in 2022. Following historic success of smallpox vaccination with vaccinia virus (VACV)-based vaccines, the third generation modified vaccinia Ankara (MVA)-based vaccine was used as prophylaxis for MPXV, but its effectiveness remains poorly characterized. Here, we applied two assays to quantify neutralizing antibodies (NAbs) in sera from control, MPXV-infected, or MVA-vaccinated individuals. Various levels of MVA NAbs were detected after infection, historic smallpox, or recent MVA vaccination. MPXV was minimally sensitive to neutralization. However, addition of complement enhanced detection of responsive individuals and NAb levels. Anti-MVA and -MPXV NAbs were observed in 94% and 82% of infected individuals, respectively, and 92% and 56% of MVA vaccinees, respectively. NAb titers were higher in individuals born before 1980, highlighting the impact of historic smallpox vaccination on humoral immunity. Altogether, our results indicate that MPXV neutralization is complement dependent and uncover mechanisms underlying vaccine effectiveness.< Réduire

Mots clés en anglais

mpox virus

neutralizing antibodies

complement

smallpox vaccination

hybrid immunity

URI

https://oskar-bordeaux.fr/handle/20.500.12278/199310

DOI

http://dx.doi.org/10.1016/j.chom.2023.05.001

Project ANR

Initiative for the creation of a Vaccine Research Institute
Integrative Biology of Emerging Infectious Diseases
Protéomique du SARS-CoV-2
Conséquences de l'infection par le SRAS-CoV-2 sur la fonction mitochondriale - ANR-21-CO14-0007

Unités de recherche

MFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234